Literature DB >> 25117705

YAPping about differentiation therapy in muscle cancer.

Matthew N Svalina1, Charles Keller2.   

Abstract

Overcoming a presumed differentiation block in the childhood muscle cancer embryonal rhabdomyosarcoma is often thought to hold promise as an approach to replace cytotoxic chemotherapy with molecularly-targeted differentiation therapies. In this issue of Cancer Cell, Tremblay and colleagues implicate YAP1 and the Hippo signaling pathway in the maintenance of differentiation-arrested and proliferative phenotypes for embryonal rhabdomyosarcoma.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25117705      PMCID： PMC4133734          DOI： 10.1016/j.ccr.2014.07.011

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

1.  Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression.

Authors:  Lisa E S Crose; Kathleen A Galindo; Julie Grondin Kephart; Candy Chen; Julien Fitamant; Nabeel Bardeesy; Rex C Bentley; Rene L Galindo; Jen-Tsan Ashley Chi; Corinne M Linardic
Journal:  J Clin Invest       Date:  2013-12-16       Impact factor: 14.808

2.  Differentiation of rhabdomyosarcoma cell lines using retinoic acid.

Authors:  Jason W Barlow; Joe C Wiley; Marieke Mous; Aru Narendran; Matthew F W Gee; Michael Goldberg; Elizabeth Sexsmith; David Malkin
Journal:  Pediatr Blood Cancer       Date:  2006-11       Impact factor: 3.167

3.  Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells.

Authors:  P L Puri; Z Wu; P Zhang; L D Wood; K S Bhakta; J Han; J R Feramisco; M Karin; J Y Wang
Journal:  Genes Dev       Date:  2000-03-01       Impact factor: 11.361

Review 4.  Retinoid therapy of childhood cancer.

Authors:  C P Reynolds; R S Lemons
Journal:  Hematol Oncol Clin North Am       Date:  2001-10       Impact factor: 3.722

5.  Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.

Authors:  Jack F Shern; Li Chen; Juliann Chmielecki; Jun S Wei; Rajesh Patidar; Mara Rosenberg; Lauren Ambrogio; Daniel Auclair; Jianjun Wang; Young K Song; Catherine Tolman; Laura Hurd; Hongling Liao; Shile Zhang; Dominik Bogen; Andrew S Brohl; Sivasish Sindiri; Daniel Catchpoole; Thomas Badgett; Gad Getz; Jaume Mora; James R Anderson; Stephen X Skapek; Frederic G Barr; Matthew Meyerson; Douglas S Hawkins; Javed Khan
Journal:  Cancer Discov       Date:  2014-01-23       Impact factor: 39.397

6.  The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation.

Authors:  Riccardo Taulli; Francesca Bersani; Valentina Foglizzo; Alessandra Linari; Elisa Vigna; Marc Ladanyi; Thomas Tuschl; Carola Ponzetto
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

7.  Overexpression of the immunoglobulin superfamily members CDO and BOC enhances differentiation of the human rhabdomyosarcoma cell line RD.

Authors:  Marta Wegorzewska; Robert S Krauss; Jong-Sun Kang
Journal:  Mol Carcinog       Date:  2003-05       Impact factor: 4.784

8.  Glycogen synthase kinase 3 inhibitors induce the canonical WNT/β-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma.

Authors:  Eleanor Y Chen; Michael T DeRan; Myron S Ignatius; Kathryn Brooke Grandinetti; Ryan Clagg; Karin M McCarthy; Riadh M Lobbardi; Jillian Brockmann; Charles Keller; Xu Wu; David M Langenau
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-24       Impact factor: 11.205

9.  Preclinical research: Design animal studies better.

Authors:  Malcolm R Macleod
Journal:  Nature       Date:  2014-06-05       Impact factor: 49.962

10.  The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation.

Authors:  Annie M Tremblay; Edoardo Missiaglia; Giorgio G Galli; Simone Hettmer; Roby Urcia; Matteo Carrara; Robert N Judson; Khin Thway; Gema Nadal; Joanna L Selfe; Graeme Murray; Raffaele A Calogero; Cosimo De Bari; Peter S Zammit; Mauro Delorenzi; Amy J Wagers; Janet Shipley; Henning Wackerhage; Fernando D Camargo
Journal:  Cancer Cell       Date:  2014-07-31       Impact factor: 31.743
  10 in total
  5 in total

Review 1.  YAP and the Hippo pathway in pediatric cancer.

Authors:  Atif A Ahmed; Abdalla D Mohamed; Melissa Gener; Weijie Li; Eugenio Taboada
Journal:  Mol Cell Oncol       Date:  2017-02-25

2.  Hedgehog-driven myogenic tumors recapitulate skeletal muscle cellular heterogeneity.

Authors:  Simone Hettmer; Michael M Lin; Daria Tchessalova; Sara J Tortorici; Alessandra Castiglioni; Tushar Desai; Junhao Mao; Andrew P McMahon; Amy J Wagers
Journal:  Exp Cell Res       Date:  2015-10-13       Impact factor: 3.905

3.  MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.

Authors:  Marielle E Yohe; Berkley E Gryder; Jack F Shern; Young K Song; Hsien-Chao Chou; Sivasish Sindiri; Arnulfo Mendoza; Rajesh Patidar; Xiaohu Zhang; Rajarashi Guha; Donna Butcher; Kristine A Isanogle; Christina M Robinson; Xiaoling Luo; Jin-Qiu Chen; Ashley Walton; Parirokh Awasthi; Elijah F Edmondson; Simone Difilippantonio; Jun S Wei; Keji Zhao; Marc Ferrer; Craig J Thomas; Javed Khan
Journal:  Sci Transl Med       Date:  2018-07-04       Impact factor: 17.956

4.  The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization.

Authors:  Lei Li; Tongzheng Liu; Yunhui Li; Chenming Wu; Kuntian Luo; Yujiao Yin; Yuping Chen; Somaira Nowsheen; Jinhuan Wu; Zhenkun Lou; Jian Yuan
Journal:  Oncogene       Date:  2018-02-16       Impact factor: 9.867

5.  Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.

Authors:  Narendra Bharathy; Noah E Berlow; Eric Wang; Jinu Abraham; Teagan P Settelmeyer; Jody E Hooper; Matthew N Svalina; Zia Bajwa; Martin W Goros; Brian S Hernandez; Johannes E Wolff; Ranadip Pal; Angela M Davies; Arya Ashok; Darnell Bushby; Maria Mancini; Christopher Noakes; Neal C Goodwin; Peter Ordentlich; James Keck; Douglas S Hawkins; Erin R Rudzinski; Atiya Mansoor; Theodore J Perkins; Christopher R Vakoc; Joel E Michalek; Charles Keller
Journal:  Skelet Muscle       Date:  2019-05-21       Impact factor: 4.912
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.